Cost Effectiveness and Resource Allocation

Fig. 3 | Cost Effectiveness and Resource Allocation

Fig. 3

From: Cost-effectiveness analysis of ceritinib vs. crizotinib in previously untreated anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) in Hong Kong

Fig. 3

ISSN: 1478-7547

Contact us

Submission enquiries: Access here and click Contact Us
General enquiries: info@biomedcentral.com